logo-alt.png
Pharmerging Market is estimated to be US$ 4426.72 billion by 2030 with a CAGR of 16.5% during the forecast period - By PMI
July 04, 2022 09:45 ET | PMI
Covina, July 04, 2022 (GLOBE NEWSWIRE) -- Particularly in the worldwide emerging economies, the Pharmerging industry is growing significantly. Some of the main drivers of this market's expansion are...
Press release Biocartis Group NV: Biocartis Announces New Agreement with AstraZeneca for the Development and Marketing of a Companion Diagnostic Test for Tagrisso®
June 22, 2022 01:00 ET | Biocartis NV
PRESS RELEASE: 22 June 2022, 07:00 CEST Biocartis Announces New Agreement with AstraZeneca for the Development and Marketing of a Companion Diagnostic Test for Tagrisso® Mechelen, Belgium, 22 June...
Persbericht Biocartis Group NV: Biocartis kondigt nieuwe overeenkomst aan met AstraZeneca voor de ontwikkeling en marketing van een companion diagnostic test voor Tagrisso®
June 22, 2022 01:00 ET | Biocartis NV
PERSBERICHT: 22 juni 2022, 07:00 CEST Biocartis kondigt nieuwe overeenkomst aan met AstraZeneca voor de ontwikkeling en marketing van een companion diagnostic test voor Tagrisso® Mechelen, België,...
fortressbio1.jpg
Fortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AstraZeneca
October 06, 2021 08:00 ET | Fortress Biotech, Inc.
Triggers upfront payment of approximately $150 million to Caelum shareholders, of which approximately $64 million is payable to Fortress Biotech1 NEW YORK and BORDENTOWN, N.J., Oct. 06, 2021 ...
5ef2af588104f70ce6d76d97_1.jpg
Global WholeHealth Partners Corp (OTC: GWHP) to Announce that Global is Now Offering All 4 Major Vaccines (AstraZeneca, J&J, Pfizer, Moderna) as Mentioned in 8k Filings 03/08/21, 06/09/21, 06/15/21, and 06/24/21
August 09, 2021 07:00 ET | Global WholeHealth Partners Corp.
The Vaccines Have Been Verified to Assist in the Protection Against the Delta Variant SAN CLEMENTE, CA, Aug. 09, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Global WholeHealth Partners Corp...
Dyadic Logo Current.jpg
Dyadic Announces Technology Transfer and Licensing Agreement With South Africa’s Rubic Consortium Aiming to Develop and Commercialize Vaccines for Distribution Throughout the African Continent
July 27, 2021 08:20 ET | Dyadic International, Inc.
Arrangement includes C1 COVID-19 vaccine technology transfer and licensing agreementProvides potential funding pathway for a C1 manufactured COVID-19 vaccine to progress through Phase II and Phase III...
FStar.jpg
F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors
July 08, 2021 08:00 ET | F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company...
logo-alt.png
Global Protein Tyrosine Kinase 7 Market is estimated with a CAGR of 5.8% during the forecast period - by PMI
June 10, 2021 10:35 ET | PMI
Covina, CA, June 10, 2021 (GLOBE NEWSWIRE) -- The global protein tyrosine kinase 7 market is anticipated to register a CAGR of 5.8%. Tyrosine-protein kinase-like 7, also known as colon carcinoma...
Logo.png
Cushing's Syndrome Pipeline Advances with a Heightened R&D, Expected Entry of Several Novel Therapies, and Inclined Interest of Pharma Companies | DelveInsight
May 26, 2021 20:00 ET | DelveInsight Business Research LLP
Los Angeles, USA, May 26, 2021 (GLOBE NEWSWIRE) -- Cushing's Syndrome Pipeline Advances with a Heightened R&D, Expected Entry of Several Novel Therapies, and Inclined Interest of Pharma...
logo-alt.png
Global Cancer ALK Inhibitor Market is estimated to be US$ 10.6 billion by 2030 with a CAGR of 22.0% during the forecast period - by PMI
April 16, 2021 10:05 ET | PMI
Covina, CA, April 16, 2021 (GLOBE NEWSWIRE) -- The Global Cancer ALK Inhibitor Market accounted for US$ 1.5 billion in 2020 and is estimated to be US$ 10.6 billion by 2030 and is anticipated to...